Endorsed by

AASLD
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

In Educational collaboration with

American Diabetes Association®



Sun Pharma's
Liver Learning
Series

ADVANCED COURSE IN METABOLIC LIVER DISEASE

Launching Soon

Scan To Register

Register now

Scientific Initiative by

centrix®

Supported by

SUN PHARMA



Sun Pharma's
Liver Learning
Series

ADVANCED COURSE IN METABOLIC LIVER DISEASE

Why This Course?

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are increasingly recognized as important cardiometabolic comorbidities among people with type 2 diabetes, prediabetes, obesity, and cardiovascular risk factors.

Early recognition, risk stratification and timely management are critical across the spectrum of MASLD, MASH and chronic liver disease. Through expert-led live sessions supported by focused study modules, this course provides practical, evidence-based approaches to clinical evaluation, noninvasive assessment, fibrosis risk stratification, and the integration of cardiometabolic risk management into liver care.

What You Will Learn?

By the end of this course, participants will be able to:

- Identify and clinically evaluate MASLD and MASH at an earlier stage in people with type 2 diabetes, prediabetes, obesity and cardiovascular risk factors.
- Apply biomarkers, noninvasive screening and fibrosis risk stratification tools to support early detection and referral decisions in MASLD/MASH.
- Assess and manage common chronic liver diseases, including recognition of alternative and coexisting etiologies in patients presenting with hepatic steatosis.
- Analyze the bidirectional relationship between MASLD/MASH and cardiometabolic disease to guide integrated care.
- Evaluate alcohol-associated liver disease and MetALD, and apply stage-appropriate management where alcohol and metabolic dysfunction coexist.
- Develop evidence-based management plans that integrate liver health, diabetes care, weight management and cardiovascular risk reduction.

Educational Collaboration

The program has been developed in educational collaboration with AASLD and ADA. AASLD has reviewed the overall educational program. ADA's educational collaboration focuses on program content related to MASLD/MASH, diabetes and cardiometabolic risk.

Course Format

Study modules	• 3 short study modules providing background and clinical context for each live session • Reading & audio learning formats
Live Virtual Sessions	• 3 expert-led virtual sessions • Interactive case-based discussions with International and Indian experts
Certificate of Completion	Be among the first physicians in India to earn the AASLD & ADA Joint Certificate of Completion



Sun Pharma's
Liver Learning
Series

ADVANCED COURSE IN METABOLIC LIVER DISEASE

Course Schedule

Live Session 1

5th September 2026
Supported by expert-curated Study module

Metabolic Liver Disease | Understanding the Hepato-Metabolic Axis

Talk 1: Approach to Metabolic Liver Disease (MASLD/MASH): Early Recognition, Diagnosis and Clinical Evaluation	**Prof. Michael Trauner** Austria
Talk 2: Metabolic Liver Disease (MASLD/MASH) in Clinical Practice: Screening, Risk Stratification, and the Role of Biomarkers	**Prof. Kenneth Cusi** USA

Live Session 2

3rd October 2026
Supported by expert-curated Study module

Liver Diseases in Clinical Practice | Approach to Common & Critical Liver Conditions

Talk 3: MASLD/MASH and Common Chronic Liver Diseases: Diagnosis, Risk Stratification & Contemporary Management	**Prof. Arun Sanyal** USA
Talk 4: Metabolic Dysfunction (MASLD/MASH) and Chronic Liver Disease: An Integrated Clinical Approach	**Dr. Richard Pratley** USA

Live Session 3

19th December 2026
Supported by expert-curated Study module

Alcohol, Metabolism and the Liver | Integrated Clinical Care

Talk 5: Case-based Approach to Alcohol-Associated Liver Disease, MetALD and Metabolic Liver Disease	**Dr. Patrick Kamath** USA
Talk 6: Integrating Liver Care with Cardiometabolic Risk Management - A Practical Framework	**Prof. Naveed Sattar** UK

Assessment

20th December 2026

Certificate of Completion – Rollout December 2026



From the makers of

Ursocol® NF

Nor-ursodeoxycholic Acid 500mg

℞ Ursocol 300

Ursodeoxycholic Acid

Scientific Initiative by

centrix®

Supported by

SUN PHARMA